The efficiency of cardiovascular risk assessment: Do the right patients get statin treatment?

Heart

Volumn 99, Issue 21, 2013, Pages 1597-1602

  Van Staa, Tjeerd Pieter ^a,b,c   Smeeth, Liam ^c   Ng, Edmond S W ^a,c   Goldacre, Ben ^c   Gulliford, Martin ^d  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b UTRECHT UNIVERSITY   (Netherlands)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENERAL PRACTICE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; POPULATION RESEARCH; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; UNITED KINGDOM;

ADULT; AGED; CARDIOVASCULAR DISEASES; DECISION SUPPORT TECHNIQUES; DRUG PRESCRIPTIONS; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; DYSLIPIDEMIAS; FEMALE; GREAT BRITAIN; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885177906     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-303698     Document Type: Article

References (21)

1. Taylor F, Ward K, Moore T.H., et al Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011; (1): CD004816.
2. Cooper A, Nherera L, Calvert N., et al. Clinical Guidelines and Evidence Review for Lipid Modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2007.
3. British Cardiac Society, British Hypertension Society, Diabetes UK. JBS guidelines on prevention of CVD in clinical practice. Heart 2005; 91: 1-52.
4. Putting prevention first-vascular checks: risk assessment and management (April 2008) NHS Health Check Programme. ww.healthcheck.nhs.uk/document.php?o= 224
5. Anderson KM, Odell PM, Wilson PWF, et al Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-8.
6. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to the cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007; 2: 172-6. (Pubitemid 46180289)
7. Hippisley-Cox J., Coupland C, Vinogradova Y., et al Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007; 335(7611): 136 doi:10.1136/bmj.39261.471806.55. (Pubitemid 47172233)
8. Hippisley-Cox J., Coupland C, Vinogradova Y., et al Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008; 336: 1475-82. (Pubitemid 351977019)
9. Siontis GC, Tzoulaki I, Siontis K.C., et al Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ 2012; 344: e3318.
10. Collins GS, Altman DG Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2. BMJ 2012; 344: e4181.
11. Williams T, van Staa TP, Puri S, et al Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf 2012; 3: 89-99.
12. Herrett E, Thomas SL, Schoonen W.M., et al Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4-14.
13. National Institute for Health and Clinical Excellence. Quality and outcomes framework (QOF) indicator guidance; indicator area: primary prevention of cardiovascular disease. http://www.nice.org.uk/nicemedia/live/13520/55454/ 55454.pdf
14. Sterne JA, White IR, Carlin J.B., et al Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009; 338: b2393.
15. Rose G. Rose's strategy of preventive medicine. New York: Oxford University Press Inc, 2008.
16. Prasad V, Vandross A. Cardiovascular primary prevention: how high should we set the bar? Archives Intern Med 2012; 172: 656-7.
17. Cholesterol Treatment Trialists' Ctt Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380 (9841): 581-90.
18. Ebrahim S, Casas JP Statins for all by the age of 50 years? Lancet 2012; 380 (9841): 545-7.
19. Gulliford MC, Charlton J, Ashworth M., et al Selection of medical diagnostic codes for analysis of electronic patient records. Application to stroke in a primary care database. PLoS One 2009; 4: e7168.
20. van Staa T.P., Goldacre B, Gulliford M., et al Randomised Evaluations of Accepted Choices in Treatment (REACT) trials: large-scale pragmatic trials within databases of routinely collected electronic healthcare records. BMJ 2012; 344: e55.
21. Holland WW, Breeze E, Swan AV Clinical trials: some reflections. Stat Med 1982; 1: 361-8. (Pubitemid 13114562)